The strategic refocusing achieved by Victhom bears the anticipated fruit
QUEBEC, June 10 /CNW Telbec/ - At the annual meeting of Victhom Human
Bionics Inc. (TSX: VHB) held June 9, 2008, the Acting President and Chief
Financial Officer of the Company, Mr. Normand Rivard, announced that based on
expected clinical development plan, the Neurostep(TM) will be ready for
commercialization in 2009. He also emphasized that the development of the next
generation of the Power Knee(TM) is progressing well, on plan, to be completed
later this year.
In neuromodulation, the Company is currently pursuing the clinical trial
of the Neurostep(TM), after the first patient was implanted in December 2007
in Canada. The trial already demonstrated promising results last April with
regards to the efficacy of the Closed-Loop neuromodulation System (CLS) for
sensing and stimulation of peripheral nerves.
The Neurostep(TM) targets the treatment of foot drop in patients with
gait disorder secondary to stroke or other nervous system pathologies.
Concerning the orthotic and prosthetic (O&P) field, the next generation
of the Power Knee(TM) will feature significant improvements as compared with
the first generation of this motorized prosthesis already available on the
market. This new product has been developed in collaboration with the company
Ossur, the commercial and technological partner of Victhom in the O&P market.
"We are very happy to note that the strategic refocusing of our R&D
activities initiated a year and a half ago has allowed the Company to
successfully develop two products that provide great therapeutic and
commercial possibilities. Victhom today leans on two solid and high-potential
business units, each presenting an outstanding opportunity for creating value
for shareholders of the Company", stated Mr. Rivard.
Victhom discovers, develops and manufactures bionic devices involved in
the treatment of a variety of physical and physiological dysfunctions.
Victhom's Neurobionix business unit focuses on the development and
commercialization of technologies and products involving implantable devices
that feature neurosensing and neurostimulation components, integrated with
artificial intelligence. Victhom's Biotronix business unit develops
biomechatronic products to support or replace peripheral limbs in what is
known as the orthotics and prosthetics market.
(*) Forward-looking statements contained in this press release involve
known and unknown risks, uncertainties or other factors that may cause actual
results, performance or achievements of the Company to be materially different
from any future results, performance or achievements expressed or implied by
such forward-looking statements.
For further information:
For further information: Victhom Human Bionics: Normand Rivard, Acting
President and CFO, (418) 872-5665, ext. 106, email@example.com;
www.victhom.com; Media Relations: Frédéric Tremblay, HKDP Communications and
Public Affairs, (514) 395-0375, ext. 234, firstname.lastname@example.org; Source:
Victhom Human Bionics Inc.